AnaptysBio

AnaptysBio focuses on the generation of immuno-oncology drugs. Read more

107 Followers on Owler
107 Followers on Owler
107 Followers on Owler
107 Followers on Owler

AnaptysBio

AnaptysBio focuses on the generation of immuno-oncology drugs. Read more

Hamza Suria's photo - President & CEO of AnaptysBio

President & CEO

Hamza Suria

CEO Approval Rating

87/100

Founded:

2005

Status:

PublicIndependent CompanyNASDAQANAB

ANAPTYSBIO TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Mersana is AnaptysBio's top competitor. Mersana was founded in 2001 in Cambridge, Massachusetts. Mersana competes in the field. Mersana generates $70.4M less revenue than AnaptysBio.

Medexus is perceived as one of AnaptysBio's biggest rivals. Medexus's headquarters is in Verdun, Quebec, and was founded in 2013. Like AnaptysBio, Medexus also competes in the Pharmaceuticals industry. Medexus generates 92% of AnaptysBio's revenue.

CytomX is one of AnaptysBio's top competitors. CytomX is a Public company that was founded in South San Francisco, California in 2008. Like AnaptysBio, CytomX also competes in the Pharmaceuticals field. CytomX has 68 more employees vs. AnaptysBio.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Igenica a competitor of AnaptysBio?

AnaptysBio Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$71.2M

AnaptysBio's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 72.6M. Over the last four quarters, AnaptysBio's revenue has decreased by 78.4%. Specifically, in Q1 2021's revenue was $11.2M; in Q4 2020, it was $52M; in Q3 2020, it was $52M; in Q2 2020, AnaptysBio's revenue was $52M.

AnaptysBio Acquisitions

No recent acquisitions found related to AnaptysBio

AnaptysBio Funding History

Since AnaptysBio was founded in 2005, it has participated in 7 rounds of funding. In total AnaptysBio has raised $158.8M. AnaptysBio's last funding round was on Jan 2017 for a total of $75.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jan 2017
$75M
-
Series D
Jul 2015
$40.8M
Debt
Aug 2013
$2M
-
Equity
Oct 2011
$8M
-
Equity
Jan 2011
$14.4K
-

Since AnaptysBio was founded in 2005, it has participated in 7 rounds of funding. In total AnaptysBio has raised $158.8M. AnaptysBio's last funding round was on Jan 2017 for a total of $75.0M

AnaptysBio Investments

No recent investments found related to AnaptysBio

AnaptysBio News

April 22, 2021MarketScreener

AnaptysBio Says JEMPERLI Drug Gets FDA Approval

(marketscreener.com) By Adriano Marchese AnaptysBio Inc. said Thursday that the U.S. Food and Drug Ad... See more »
March 8, 2021Benzinga

AnaptysBio's Imsidolimab Fails To Separate From Placebo In Skin Blistering Disorder Study

AnaptysBio Inc (NASDAQ: ANAB) reports disappointing top-line data from its Phase 2 (POPLAR) trial of ... See more »
March 8, 2021Endpoints News

AnaptysBio takes a beating as its lead drug fails its first PhII test. And 5 more trials are nearing a readout

AnaptysBio shares got hammered Monday morning after the biotech conceded defeat for the first mid-sta... See more »
January 7, 2021Benzinga

AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotech... See more »
December 8, 2020Zolmax News

Thrivent Financial for Lutherans Sells 15,950 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Thrivent Financial for Lutherans cut its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 16.4% in the thir... See more »

AnaptysBio Press Releases

October 13, 2020StreetInsider

AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)

6 of 8 patients achieved primary endpoint of improvement in the clinical global impression scale (CGI... See more »
September 1, 2020GlobalNewswire

Bragar Eagel & Squire, P.C. is Investigating AnaptysBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized sha... See more »
August 5, 2020GlobeNewswire

AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotec... See more »
May 6, 2020GlobeNewswire

AnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates

SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotech... See more »
April 18, 2020GlobalNewswire

KSF REMINDS ANAB, BBBY, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, April 17, 2020 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, forme... See more »
April 14, 2020NewsFile

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - April 14, 2020) - Faruqi & Faruqi, LLP, a leading national secu... See more »
April 12, 2020centralcharts

Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. ... See more »

Social Media

AnaptysBio Headquarters

10421 Pacific Center Court Suite 200

San Diego, California92121

858-362-6295

Driving Directions »

Trending Companies

AnaptysBio Summary

ABOUT

Overview

AnaptysBio focuses on the generation of immuno-oncology drugs. AnaptysBio was founded in 2005. AnaptysBio's headquarters is located in San Diego, California, USA 92121. It has raised 158.8M in 7 rounds. The latest round was in Jan 2017. Some of Anapty...

CEO

AnaptysBio's President & CEO, Hamza Suria, currently has an approval rating of 87%. AnaptysBio's primary competitors are Mersana, Medexus & CytomX.

Website

anaptysbio.com

Frequently Asked Questions about AnaptysBio

  1. When was AnaptysBio founded?

    AnaptysBio was founded in 2005
  2. Who is AnaptysBio's CEO?

    AnaptysBio's CEO is Hamza Suria
  3. How much revenue does AnaptysBio generate?

    AnaptysBio generates $71.2M in revenue
  4. How much funding does AnaptysBio have?

    AnaptysBio has historically raised $158.8M in funding
  1. Where is AnaptysBio's headquarters?

    AnaptysBio's headquarters is in San Diego California, USA
  2. How many employees does AnaptysBio have?

    AnaptysBio has 78 employees
  3. What sector does AnaptysBio operate in?

    AnaptysBio is in Pharmaceuticals
  4. Who are AnaptysBio's competitors?

    AnaptysBio's top competitors are Mersana, Medexus, CytomX